首页> 外文学位 >Natural products as a source of new therapies for neurodegenerative disease and efforts toward the development of a metabolomics-based drug discovery platform.
【24h】

Natural products as a source of new therapies for neurodegenerative disease and efforts toward the development of a metabolomics-based drug discovery platform.

机译:天然产物可作为神经退行性疾病新疗法的来源,并致力于开发基于代谢组学的药物发现平台。

获取原文
获取原文并翻译 | 示例

摘要

Natural products have traditionally played an important role in drug discovery research. They have been particularly important in the search for therapies for neurodegenerative diseases. Although there are numerous forms of neurodegenerative diseases, the disorders associated with protein misfolding (e.g. Alzheimer's, Parkinson's, Huntington's and prion diseases) represent a unique area for natural products drug discovery as these diseases share many pathological features, suggesting that therapies developed for any one of these diseases may have applications for the others. There have been many reports of secondary metabolites with biological activities related to neurodegeneration associated with protein misfolding, and emerging drug targets for these diseases are fueling interest in finding natural products which can serve as leads for therapeutic development. The literature surrounding the topic of natural products and neurodegenerative disease has been summarized in the first chapter of this dissertation.;Although there have already been many natural products identified as potential therapeutic leads for neurodegenerative diseases, there is still a significant need for the enhancement of methodologies used for bioassay screening of secondary metabolites. Metabolomic approaches to drug discovery have the potential to combine the advantages of phenotypic disease models and molecular target assays. The metabolomic examination of a phenotypic disease model can provide detailed information concerning the molecular target and/or the mechanism of action of a compound while simultaneously revealing its phenotypic effects. The third chapter of this dissertation describes the metabolomic examination of a phenotypic model of Huntington's disease. This detailed exploration of the metabolic changes associated with mutant huntingtin toxicity has revealed many intriguing new insights into the specific processes which are involved in the cellular response to protein aggregation. The results in this chapter show that the metabolic response of cells to mutant huntingtin can be detected using a metabolomic approach and that these metabolic changes can be used to identify potential therapeutic targets for Huntington's disease. These results also show the importance of the metabolites alanine, glutamine, glycerol and valine in the metabolic response to mutant huntingtin in multiple species. This work provides the foundation for the future development of a metabolomic-based drug discovery platform for natural products.;In the fourth chapter of this dissertation, the use of metabolic profiling to examine the protective role of the metabolite trehalose is described. Trehalose is a disaccharide that has been previously identified as having therapeutic implications for neurodegenerative diseases. In order to explore the role that trehalose plays in the yeast model of Huntington's disease, a series of yeast strains with gene deletions for each step in the metabolic cycle of trehalose were engineered to express normal and mutant huntingtin protein fragments. One of these gene deletion strains, deficient in the production of the acid trehalase protein, exhibited a prounouced reduction in the toxicity associated with mutant huntingtin, the aggregation of mutant huntingtin and the elimination of the metabolic aberrations associated with mutant huntingtin expression. This investigation of the role of trehalose in the yeast model of Huntington's disease provides evidence for the therapeutic potential of the manipulation of chemical chaperone systems in mammalian cells.;The final chapter of this dissertation diverges from the topic of neurodegeneration and instead describes the isolation and characterization of a series of briarane diterpenes from a Briareum sp. of octocoral. The ichthyotoxic properties of these compounds are described as well as their metabolic transformation by fish. The scientific merits of this study make it an important and significant part of my doctoral research and demonstrate the multidisciplinary nature of my research.
机译:传统上,天然产物在药物发现研究中起着重要作用。在寻找神经退行性疾病的疗法中,它们特别重要。尽管存在多种形式的神经退行性疾病,但与蛋白质错误折叠相关的疾病(例如阿尔茨海默氏病,帕金森氏病,亨廷顿氏病和病毒病)代表了天然产物药物发现的独特领域,因为这些疾病具有许多病理学特征,这表明针对任何一种人开发的疗法这些疾病中的一些可能对其他疾病有应用。已经有许多关于具有与蛋白质错误折叠相关的神经变性相关的生物学活性的次生代谢产物的报道,这些疾病的新兴药物靶标正激发人们对寻找可以用作治疗开发先导的天然产物的兴趣。本论文的第一章概述了有关天然产物和神经退行性疾病的文献。尽管已经有许多天然产物被确定为神经退行性疾病的潜在治疗先导,但仍然存在对增强神经退行性疾病的巨大需求。用于次生代谢物生物测定筛选的方法。药物发现的代谢组学方法有可能将表型疾病模型和分子靶标分析的优势结合起来。表型疾病模型的代谢组学检查可以提供有关化合物的分子靶标和/或作用机理的详细信息,同时揭示其表型效应。本文的第三章描述了亨廷顿氏病表型模型的代谢组学研究。对与突变型亨廷顿蛋白毒性相关的代谢变化的详细研究揭示了许多有趣的新见解,它们涉及细胞对蛋白质聚集反应的特定过程。本章中的结果表明,可以使用代谢组学方法检测细胞对突变型亨廷顿蛋白的代谢反应,并且这些代谢变化可用于确定亨廷顿氏病的潜在治疗靶标。这些结果还显示了代谢物丙氨酸,谷氨酰胺,甘油和缬氨酸在多种物种对亨廷顿蛋白突变的代谢反应中的重要性。这项工作为基于代谢组学的天然产物药物发现平台的未来开发提供了基础。在本论文的第四章中,描述了利用代谢谱分析来检查代谢物海藻糖的保护作用。海藻糖是一种先前已被确定对神经退行性疾病具有治疗意义的二糖。为了探索海藻糖在亨廷顿氏病的酵母模型中的作用,对一系列在海藻糖代谢周期中每个步骤均具有基因缺失的酵母菌株进行了工程改造,以表达正常的和突变的亨廷顿蛋白片段。这些基因缺失菌株之一,缺乏酸性海藻糖酶蛋白的产生,与突变亨廷顿蛋白相关的毒性,突变亨廷顿蛋白的聚集和与突变亨廷顿蛋白表达相关的代谢异常的消除均表现出极大的降低。海藻糖在亨廷顿舞蹈症酵母模型中的作用研究为在哺乳动物细胞中操纵化学分子伴侣系统提供了治疗潜力。本论文的最后一章与神经退行性疾病有所不同,而是描述了分离和分离方法。野蔷薇属中一系列芳构烷烃二萜的表征八音。描述了这些化合物的鱼鳞鱼的毒性以及鱼类的代谢转化。这项研究的科学价值使其成为我的博士研究的重要组成部分,并证明了我研究的多学科性质。

著录项

  • 作者

    Joyner, Phillip M.;

  • 作者单位

    The University of Oklahoma.;

  • 授予单位 The University of Oklahoma.;
  • 学科 Chemistry Biochemistry.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 156 p.
  • 总页数 156
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号